A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

Lignende værker

• Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
  af: Manasanch, Elisabet E., et al.
  Udgivet: (2020)
• Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
  af: Shah, Jatin J., et al.
  Udgivet: (2015)
• A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
  af: Lee, Hans C., et al.
  Udgivet: (2021)
• A Phase 1/2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma
  af: Shah, Jatin J., et al.
  Udgivet: (2017)
• Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
  af: Chari, Ajai, et al.
  Udgivet: (2019)